Drug Trial Radar · NCT05423262
A Study of TRK-950 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Jul 6, 2022
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Toray Industries, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
Conditions
- Solid Tumor
- Melanoma
Interventions
TRK-950Biological
5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950Biological
10 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950Biological
20 mg/kg administered intravenously over 60 minutes (bi-weekly)
NivolumabDrug
240 mg administered intravenously over 30 minutes (bi-weekly)
TRK-950Biological
10 mg/kg administered Intravenously over 60 minutes (weekly)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)Time frame: Up to Day 28
- Number of participants with adverse events (AEs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
- Number of participants with adverse events of special interest (AESIs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
- Number of participants with serious adverse events (SAEs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
- Objective response rate (ORR) (Part 3)Time frame: Up to approximately 12 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan · Recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan · Recruiting
Sapporo Medical University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan · Recruiting
Shinshu University Hospital
Matsumoto, Nagano, Japan · Recruiting
Niigata Cancer Center Hospital
Niigata, Niigata, Japan · Recruiting
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan · Recruiting
Shizuoka Cancer Center
Nagaizumi-chō, Shizuoka, Japan · Recruiting
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan · Recruiting
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.